Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 604 results
Filters: First Letter Of Title is S  [Clear All Filters]
Found 604 results.

Acquired Immunodeficiency Syndrome

Schouten JT, Krambrink A, Ribaudo HJ, et al. "Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095." Clin. Infect. Dis.. 2010;50(5):787-91.

Adult

Umeh OC, Currier JS, Park J-G, Cramer Y, Hermes AE, Fletcher CV. "Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men." J Clin Pharmacol. 2011;51(12):1665-73.
Venuto CS, Mollan K, Ma Q, et al. "Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202." J. Antimicrob. Chemother.. 2014;69(12):3300-10.
Jacobson JM, Zheng L, Wilson CC, et al. "The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection." J. Acquir. Immune Defic. Syndr.. 2016;71(2):163-71.
Robbins GK, Testa MA, Su M, et al. "Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384." HIV Clin Trials. 2013;14(5):235-53.
Swindells S, Komarow L, Tripathy S, et al. "Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2013;17(4):532-9.
Schifitto G, Yiannoutsos CT, Ernst T, et al. "Selegiline and oxidative stress in HIV-associated cognitive impairment." Neurology. 2009;73(23):1975-81.
Rosenberg ES, Graham BS, Chan ES, et al. "Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection." PLoS ONE. 2010;5(5):e10555.
Sherman KE, Andersen JW, Butt AA, et al. "Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C)." J. Acquir. Immune Defic. Syndr.. 2010;55(5):597-605.
Naggie S, Marks KM, Hughes M, et al. "Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C." Clin. Infect. Dis.. 2017;64(8):1035-1042.
Palmer S, Boltz V, Maldarelli F, et al. "Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy." AIDS. 2006;20(5):701-10.
Wilkin T, Lee JY, Lensing SY, et al. "Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men." J. Infect. Dis.. 2010;202(8):1246-53.
Haas DW, Kwara A, Richardson DM, et al. "Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes." J. Antimicrob. Chemother.. 2014;69(8):2175-82.
Brown TT, Smurzynski M, Wu K, Bosch RJ, McComsey GA. "Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort." Antivir. Ther. (Lond.). 2009;14(6):853-8.
Pei L, Hughes MD. "A statistical framework for quantile equivalence clinical trials with application to pharmacokinetic studies that bridge from HIV-infected adults to children." Biometrics. 2008;64(4):1117-25.
Schouten JT, Krambrink A, Ribaudo HJ, et al. "Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095." Clin. Infect. Dis.. 2010;50(5):787-91.
Hogan CM, Degruttola V, Sun X, et al. "The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals." J. Infect. Dis.. 2012;205(1):87-96.
Tebas P, Zhang J, Yarasheski K, et al. "Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)." J. Acquir. Immune Defic. Syndr.. 2007;45(2):193-200.
Dubé MP, Wu JW, Aberg JA, et al. "Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148." Antivir. Ther. (Lond.). 2006;11(8):1081-9.
Meier A, J Chang J, Chan ES, et al. "Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1." Nat. Med.. 2009;15(8):955-9.
Gulick RM, Wilkin TJ, Chen YQ, et al. "Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial." Ann. Intern. Med.. 2017;167(6):384-393.

Pages